Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p16
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 16/191)
Character Range: 9621641–9634504

and failed sequential treatment with topical permethrin and benzyl benzoate and finished the most recent course of topical therapy at least 4 weeks prior to initiating oral therapy; or
                                                                                                                                                                                                                               Patient must have a contraindication to topical treatment;
                                                                                                                                                                                                                               Patient must weigh 15 kg or over;
                                                                                                                                                                                                                               Patient must be 5 years of age or older.
C4572               P4572          CN4572           Bimatoprost with timolol                                                                                                                                                   Elevated intra-ocular pressure
                                                                                                                                                                                                                               The condition must have been inadequately controlled with monotherapy; AND
                                                                                                                                                                                                                               Patient must have open-angle glaucoma.  or
                                                                                                                                                                                                                               Patient must have ocular hypertension.
C4575               P4575          CN4575           Lanreotide                                                                                                                                                                 Functional carcinoid tumour                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 4575
                                                                                                                                                                                                                               The condition must be causing intractable symptoms; AND
                                                                                                                                                                                                                               Patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents; AND
                                                                                                                                                                                                                               Patient must be one in whom surgery or antineoplastic therapy has failed or is inappropriate; AND
                                                                                                                                                                                                                               The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 120 mg every 28 days.
                                                                                                                                                                                                                               Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.
C4576               P4576          CN4576           Macrogol 3350                                                                                                                                                              Constipation
                                                                                                                                                                                                                               Patient must have malignant neoplasia.
C4577               P4577          CN4577           Macrogol 3350                                                                                                                                                              Constipation
                                                                                                                                                                                                                               Patient must be receiving palliative care.
C4580               P4580          CN4580           Macrogol 3350                                                                                                                                                              Constipation
                                                                                                                                                                                                                               Patient must be paraplegic, quadriplegic or have severe neurogenic impairment of bowel function; AND
                                                                                                                                                                                                                               The condition must be unresponsive to other oral therapies.
C4586               P4586          CN4586           Calcium                                                                                                                                                                    Hyperphosphataemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Compliance with Authority Required procedures - Streamlined Authority Code 4586
                                                                                                                                                                                                                               The condition must be associated with chronic renal failure.
C4596               P4596          CN4596           Macrogol 3350                                                                                                                                                              Chronic constipation
                                                                                                                                                                                                                               The condition must be inadequately controlled with first line interventions such as bulk-forming agents.
C4599               P4599          CN4599           Betaine                                                                                                                                                                    Homocystinuria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Compliance with Authority Required procedures
                                                                                                                                                                                                                               The treatment must be as adjunctive therapy to current standard care; AND
                                                                                                                                                                                                                               The condition must be treated by or in consultation with a metabolic physician.
                                                                                                                                                                                                                               The name of the specialist must be included in the authority application.
C4600               P4600          CN4600           Erlotinib                                                                                                                                                                  Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures - Streamlined Authority Code 4600
                                                                                                                                                                                                                               Continuing treatment
                                                                                                                                                                                                                               The treatment must be as monotherapy; AND
                                                                                                                                                                                                                               Patient must have previously been issued with an authority prescription for this drug prior to 1 August 2014; AND
                                                                                                                                                                                                                               Patient must not have progressive disease;
                                                                                                                                                                                                                               Patient must have a wild type epidermal growth factor receptor (EGFR) gene.  or
                                                                                                                                                                                                                               Patient must have an epidermal growth factor receptor (EGFR) gene of unknown type.
C4601               P4601          CN4601           Macrogol 3350